These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18476929)

  • 1. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T
    J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.
    Nomura Y; Arata M; Koriyama C; Masuda K; Morita Y; Hazeki D; Ueno K; Eguchi T; Kawano Y
    J Pediatr; 2010 May; 156(5):786-91. PubMed ID: 20097355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease.
    Sung RY; Ng YM; Choi KC; Mok GC; Cheng YW; Ho MH;
    Pediatr Infect Dis J; 2006 Jun; 25(6):521-5. PubMed ID: 16732150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kawasaki disease presenting as cervical lymphadenitis or deep neck infection.
    Kao HT; Huang YC; Lin TY
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):468-70. PubMed ID: 11283510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
    Singh-Grewal D; Wong M; Isaacs D
    J Paediatr Child Health; 2005; 41(9-10):495-9. PubMed ID: 16150066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
    Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kawasaki disease in a pediatric intensive care unit: a case-control study.
    Dominguez SR; Friedman K; Seewald R; Anderson MS; Willis L; Glodé MP
    Pediatrics; 2008 Oct; 122(4):e786-90. PubMed ID: 18809597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
    Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ; Kim KH; Chun JK; Kim DS
    Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features of recurrent Kawasaki disease in 20 children].
    Zou LX; Gong FQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):617-9. PubMed ID: 18947484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
    J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Kawasaki disease in older children.
    Cai Z; Zuo R; Liu Y
    Clin Pediatr (Phila); 2011 Oct; 50(10):952-6. PubMed ID: 21628347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S; Safari M; Amin R
    Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.